tbuckley/cabot-search huggingface dataset:
Robust prediction of immune checkpoint inhibition therapy for non-small cell lung cancer.
Authors: Yiqun Zhang, Guodong Zhao, Ning He, Lingyu Wang, Jianfei Wang, Ge Jin, Rongbo Lin, Yadong Yang
Journal: Journal of Clinical Oncology (2020)

e15192 Background: Immune checkpoint inhibition (ICI) has been validated and applied in advanced lung cancer patients. However Oonly part of patients response to ICI, thus optimizing ICI would be emergent. Based on public non-small cell lung cancer (NSCLC) cohorts’ data, we expected to build a multivariable model which would improve the efficacy of predicting ICIs response. Methods: 2 NSCLC and 1 pan-cancer cohorts treated with ICIs were collected from cBioPortal (luad_mskcc_2015, n = 203; nsclc_pd1_msk_2018, n = 33; tmb_mskcc_2018, n = 1661, pan-cancer). Another NSCLC cohort (cancer_cell_2018) was collected from MD. Hellmann’s study (Cancer Cell, 2018, n = 75). We incorporated features including tumor mutation burden (TMB), PD-L1 expression, Mutant-Allele Tumor Heterogeneity (MATH), and mutational status of cancer-related pathways. And we used Bayesian Regularization for Feed-Forward Neural Networks ( brnn) method to fit models of predicting clinical response. Results: The correlation analysis showed that MATH was independent of TMB (R = 0.141, p = 0.01252) and PD-L1 expression (p = 0.432, ANOVA test among high, median and low PD-L1 expression group) in 3 merged NSCLC cohorts. We randomly selected 70% of cancer_cell_2018 cohort as training set, and the AUC improved from 0.5702/0.5191/0.6728 to 0.6893/0.527/0.8554 (in cancer_cell_2018 validation set, luad_mskcc_2015, and nsclc_pd1_msk_2018 cohort, respectively) after incorporating MATH to TMB + PD-L1 model. Additionally, we identified that mutational status of DDR, HRR, MAPK, Wnt, JAK, PI3K, and NFKB pathway was significantly associated with overall survival in tmb_mskcc_2018 cohort. After incorporating the mutation status of these pathways, the model exhibited further improvement in prediction efficacy (AUC reached 0.8595/0.5634/0.7831). When using luad_mskcc_2015 cohort as training set, the model performance improvement was also observed after joining pathway mutation information into TMB + PD-L1 + MATH model (AUC improved from 0.5742/0.6339 to 0.7305/0.7 in predicting luad_mskcc_2015 and cancer_cell_2018 cohort). Conclusions: We built a multivariable model with robust performance in predicting ICI response in independent NSCLC cohorts. With the accumulation of larger datasets, further studies are warranted to refine the predictive performance of the approach.
A study of skin changes that characterise different types of facial ageing
Authors: L.M. Pardo, M.A. Hamer, F. Liu, P. Velthuis, M. Kayser, D.A. Gunn, T. Nijsten
Journal: British Journal of Dermatology (2020)

Facial ageing is characterised by several skin changes, but it is not currently clear how these changes are related to each other, and how these are linked to the different types of facial ageing. This study, involving investigators from the Netherlands, China and the U.K., was designed to identify which facial changes are best associated with different types of ageing. The authors measured seven different individual features which can be identified visually. These were general (global) wrinkling, perceived age, a measure for assessing photodamage (Griffiths grading), pigmented (dark) spots, telangiectasia (spidery dilated blood vessels), actinic keratosis (patches of skin that are a pre-cancerous change) and the presence of a type of skin cancer called keratinocyte cancer, such as squamous cell carcinomas. The method they used for identifying groupings of these individual facial changes, that could be best used to identify ageing in the skin, is called ‘principal component analysis’. This is a statistical method for comparing and identifying similarities in complex data. The team's techniques for examination included facial photographs, but there was also a full skin examination in over 4,600 individuals from the Netherlands, of whom almost 1,800 had complete information on all the seven changes described above. Most (over 70%) of the features associated with ageing on the skin could be grouped into one of three different patterns. Firstly, a ‘hypertrophic component’ which included increased wrinkling, perceived age and damage associated with sun exposure. Secondly, an ‘atrophic component’ which had two main changes, pigmented spots and telangiectasia and thirdly, a ‘cancerous component’ where there were more actinic keratoses or keratinocyte skin cancers. The importance of this work it that it will allow researchers to study risk factors or preventative measures for the three main types of skin ageing using this new classification. This is a summary of the study: Principal component analysis of seven skin-ageing features identifies three main types of skin ageing
Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome.
Authors: Eric Kim, Natalia Miheecheva, Akshaya Ramachandran, Yang Lyu, Ilia Galkin, Viktor Svekolkin, Ekaterina Postovalova, Alexander Bagaev, Krystle Nomie, Anna Ogloblina, Felix Frenkel, Ravshan Ataullakhanov, James J Hsieh, Russell Kent Pachynski
Journal: Journal of Clinical Oncology (2020)

e17506 Background: The inclusion of multiparametric MRI (mpMRI) to prostate cancer (PCa) diagnostics has increased the detection rate and has improved the prediction rate of clinically significant PCa. Yet, mpMRI has a false negative rate of 12.6%, missing 6-13% of clinically significant PCa. The mechanisms underlying MRI visibility are poorly understood; therefore, to probe the molecular and cellular underpinnings of PCa MRI visibility, we profiled tissue from Gleason score and clinically matched patients with MRI-visible and MRI-invisible PCa who underwent radical prostatectomy. Methods: MRI-invisible (n = 7) and MRI-visible (n = 8) PCa tumors were evaluated with multiplex immunofluorescence (MxIF; 14 markers) and were subjected to gene expression profiling using the HTG EdgeSeq Oncology Biomarker Panel (2,549 genes). Gene expression analysis was also performed using The Cancer Genome Atlas (TCGA), including normal prostate (n = 52) and PCa (n = 387) tissue. Analyses were performed using the BostonGene automated pipeline. Results: MpMRI-visible PCa tumors (62.5%) displayed compact epithelial tumor architecture compared with mpMRI-invisible PCa tumors (28.5%). mpMRI-visible PCa had higher malignant cell density (p = 0.04) and increased neighboring malignant cells (p = 0.07), correlating with MRI-visible PCa complex tumor architecture (r = 0.49 for neighboring malignant cells vs tumor cell density). Tumor stromal organization differences were determined by measuring Wasserstein distances between distributions, and mpMRI-invisible PCa stroma appeared more similar to normal tissue. The visible group exhibited lower expression of stroma-enriched genes such as filamin C (FLNC) (FDR &lt; 0.1) and cellular adhesion-related genes (FDR &lt; 0.4), with gene expression signatures markedly different compared to normal prostate tissue. Higher malignant cell density, neighboring malignant cells, and Wasserstein distances, and low FLNC expression – all mpMRI visibility characteristics – were associated with patient relapse (p = 0.02). Low stroma signature expression in the TCGA cohort correlated with inferior PCa PFS (p = 0.005). Conclusions: This is the first integrated multi-omics analysis of clinically matched mpMRI-visible and -invisible PCa. mpMRI-invisible tumors exhibited molecular, cellular, and structural characteristics more akin to normal prostate tissue, which may render them undetectable by imaging. A stroma-associated gene signature, a mpMRI-invisible tumor feature, correlated with better PCa clinical outcomes.
Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
Authors: Julia K Rotow, Daniel Botelho Costa, Cloud P. Paweletz, Mark M. Awad, Paul Marcoux, Deepa Rangachari, David Allen Barbie, Jacob Sands, Michael L. Cheng, Bruce E. Johnson, Geoffrey R. Oxnard, David Michael Jackman, David J. Kwiatkowski, Kenneth L. Kehl, Monika D Izdebski, Christie J. Lau, Kevin A Vasquez, Pasi A. Janne
Journal: Journal of Clinical Oncology (2020)

9507 Background: First-line treatment with an EGFR tyrosine kinase inhibitor (TKI) is standard of care for patients (pts) with EGFR-mutated NSCLC. The EGFR TKI osimertinib is active against the acquired gefitinib-resistant mutation EGFR T790M, as is gefitinib against the osimertinib-resistant EGFR C797S. Preclinical evidence suggests dual EGFR inhibition with gefitinib + osimertinib may delay emergence of acquired resistance. Methods: This ongoing phase I/II study enrolled pts with stage IV EGFR-mutated (L858R or del19) NSCLC, without prior therapy for metastatic disease. Treatment in dose escalation (n = 6): concurrent osimertinib 40 mg or 80 mg + gefitinib 250 mg daily. In dose expansion (n = 21): osimertinib + gefitinib at the maximum tolerated dose (MTD). Prior to protocol amendment 6 pts received alternating monthly cycles of TKI monotherapy and were excluded from this analysis. The primary endpoints in the dose escalation and expansion phases were, respectively, identification of the MTD and feasibility, defined as receipt of combination therapy for ≥ 6 four-week cycles. Secondary endpoints included overall response rate (ORR), survival outcomes, plasma EGFR mutation clearance (cell free DNA by droplet digital PCR (ddPCR)), and mechanisms of acquired resistance. Results: From May 2017 to July 2019 27 pts were enrolled and evaluable for the primary endpoints. The MTD was osimertinib 80 mg plus gefitinib 250 mg orally daily. In feasibility analysis, 81.5% completed ≥6 cycles combination therapy (1 pt discontinued for progression, 4 for toxicity). The ORR was 85.2% (95% CI 67.5%-94.1%). Best response: 85.2% partial response, 14.8% stable disease. The most common treatment-related adverse effects (TRAEs) (% any grade, % grade 3) were rash (96.3%, 3.7%), diarrhea (85.2%, 11.1%) and dry skin (70.4%, 0%). Plasma ddPCR (n = 25 pts) detected the driver EGFR mutation at baseline in 68% of pts. In these pts, plasma EGFR cleared to undetectable at 2 weeks treatment in 82.4%. At 14.8 months median follow up the median progression free survival was not yet reached. Conclusions: Combination therapy with osimertinib and gefitinib is tolerable for first-line treatment of EGFR-mutated NSCLC and resulted in rapid plasma clearance of the EGFR mutation. The observed ORR is consistent with previously reported first-line response rates to osimertinib. Analysis of survival outcomes and acquired resistance mechanisms are pending data maturity and will facilitate understanding of the role of first-line dual EGFR TKI therapy for this pt population. Clinical trial information: NCT03122717 .
Reasonable application of Chinese traditional patent medicines and to avoid adverse reaction
Authors: 梁晓春
Journal: BMJ (2009)

中成药是在中医药理论指导下,遵循君臣佐使配伍原则,以中药材为原料,按照规定的处方、生产工艺和质量标准生产的制剂.具有易于保存、服用方便及便于携带等特点,临床应用非常广泛,中西医人员都在使用,且患者自己也可以在药店买药.在这种状况下中成药的安全问题就显得非常突出,存在药不对证、用药不规范、疗程不合理及服法不正确等诸多问题.如:凡外感,无论风寒感冒还是风热感冒一概都用感冒冲剂;只要咽喉痛都用双黄连口服液;凡是冠心病、脑梗死等都用丹参注射液、葛根素注射液等,这样既不符合中医理论,也不能起到治疗效果,甚至引起不良反应.为了保证中成药的安全有效,下面谈谈如何合理使用中成药,规避不良反应。
微管胸腔闭式引流在HIV/AIDS并胸腔积液中的应用
Authors: 张金桥, 李品银
Journal: BMJ (2010)

HIV/AIDS并发结核病是最常见的机会性感染,其中以肺结核、结核性渗出性胸膜炎和胸腔积液比较常见.中心静脉导管可以广泛地应用于临床的各个领域,如胸腔积液的治疗等[1].本研究对HIV/AIDS并胸腔积液患者使用微管(中心静脉置管)胸腔闭式引流取得较好效果,报道如下。
Noncanonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis
Authors: Donato Santovito, Virginia Egea, Kiril Bidzhekov, Lucia Natarelli, André Mourão, Xavier Blanchet, Kanin Wichapong, Maria Aslani, Coy Brunßen, Michael Horckmans, Michael Hristov, Arie Geerlof, Esther Lutgens, Mat J.A.P. Daemen, Tilman Hackeng, Christian Ries, Triantafyllos Chavakis, Henning Morawietz, Ronald Naumann, Philipp von Hundelshausen, Sabine Steffens, Johan Duchêne, Remco T.A. Megens, Michael Sattler, Christian Weber
Journal: Science Translational Medicine (2020)

Autophagy-driven nuclear transfer of miR-126-5p guided by Mex3a enables direct inhibition of caspase-3 and protects against atherosclerosis.
To enhance the cognition of clinical characters of diseases caused by herpes viruses
Authors: 邓国华
Journal: BMJ (2008)

疱疹病毒疾病是由不同的人疱疹病毒(human herpes viruses)感染所致,常见的临床类型有口唇疱疹、带状疱疹、生殖器疱疹、传染性单核细胞增多症、巨细胞病毒感染以及发病率较低的疱疹病毒脑炎等。
Mode of general practitioner training and its accomplishment in Shanghai
Authors: Lili Zhang, Rong Zhou, Kan Zhang
Journal: BMJ (2018)

In order to strengthen the training of grassroots health personnel, in Shanghai the program of general practice training has been included in the residency training systemsince 2010, and the program integrated theresidency training with master degree study. At the same time the training of general practitioners in Shanghai also included the following programs: job-transfer training for grassroots doctors, order oriented training for rural doctors, order oriented free medical education, and standardized training of assistant general practitioners.


Key words: 
General practitioner; Standardized training
消化不良
Authors: 周仲华
Journal: BMJ (2005)

无论是在就医条件较好的大城市,还是在我们去义诊的偏远、贫困的农村地区,胃区疼痛或不适都是一个很常见的问题.这样的病人往往表现为慢性或反复发作性上腹痛或不适,时常伴有饱胀感、呃逆、腹胀、烧心、厌食、恶心或呕吐等症状。
Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study
Authors: Jerrold L Vitek, Roshini Jain, Lilly Chen, Alexander I Tröster, Lauren E Schrock, Paul A House, Monique L Giroux, Adam O Hebb, Sierra M Farris, Donald M Whiting, Timothy A Leichliter, Jill L Ostrem, Marta San Luciano, Nicholas Galifianakis, Leo Verhagen Metman, Sepehr Sani, Jessica A Karl, Mustafa S Siddiqui, Stephen B Tatter, Ihtsham ul Haq, Andre G Machado, Michal Gostkowski, Michele Tagliati, Adam N Mamelak, Michael S Okun, Kelly D Foote, Guillermo Moguel-Cobos, Francisco A Ponce, Rajesh Pahwa, Jules M Nazzaro, Cathrin M Buetefisch, Robert E Gross, Corneliu C Luca, Jonathan R Jagid, Gonzalo J Revuelta, Istvan Takacs, Michael H Pourfar, Alon Y Mogilner, Andrew P Duker, George T Mandybur, Joshua M Rosenow, Scott E Cooper, Michael C Park, Suketu M Khandhar, Mark Sedrak, Fenna T Phibbs, Julie G Pilitsis, Ryan J Uitti, Philip A Starr
Journal: The Lancet Neurology (2020)
Chronic myelomonocytic leukemia genomic signature correlates with the degree of bone marrow fibrosis: A single-institutional retrospective study.
Authors: Feras Ally, Amar Jariwala, Patricia A. Aoun, Milhan Telatar, Raju K. Pillai, Haris Ali, David Snyder, Carrie Louie, Michelle Afkhami
Journal: Journal of Clinical Oncology (2020)

7559 Background: Chronic myelomonocytic leukemia (CMML) has features of both a myeloproliferative neoplasm and a myelodysplastic syndrome. The median overall survival (OS) in most series is 20-40 months. CMML is a relatively rare entity, and there is limited understanding of prognostic molecular markers. CMML associated with bone marrow fibrosis grade 1, appear to have shorter progression free survival. In this study we investigated the correlation of mutations with bone marrow reticulin fibrosis in patients with CMML. Methods: We investigated a cohort of 41 consecutive patients diagnosed with CMML 0, 1, 2, and CMML-AML from 2014 to 2019 at our institute. The median age of 41 patients was 68 years (range, 34-82). 27% were females and 73% were males. This cohort consists of 8 (20%) patients with CMML0, 19 (46%) with CMML1, 8 (20%) with CMML2 and 6 (15%) with CMML-AML. Genomic DNA was extracted from the bone marrow aspirates and targeted mutation NGS libraries were prepared from 200 ng of genomic DNA using the SureSelect target enrichment system (Agilent Technologies Inc.). The gene panel consists of 73 genes focused on myeloid neoplasms. The data were curated on the basis of our molecular pathology and national databases. Additionally, clinical data and bone marrow (BM) reticulin fibrosis grades (n = 27 available) were retrieved from the patient’s medical record. Results: The mutational profile frequency in our cohort showed that the most common mutations were TET2 (31%), ASXL1 (31%), and SRSF2 (23%), with frequencies very similar to those reported in the literature. Of the 27 cases with an available reticulin stain, only low grade fibrosis (MF-0, n = 18. MF-1, n = 9) were identified in our cohort. The frequencies of mutations in ASXL1, U2AF1, TP53, JAK2 and RUNX1, positively correlated with low grade fibrosis (MF-1). Additionally, patients with higher frequencies of SRSF2, TET2, and SETBP1 mutations showed no fibrosis (MF-0). Conclusions: This study is the first to correlate the degree of fibrosis with the frequency of mutations in CMML. We found similar mutations spectrum reported in the literature in patients with CMML. The mutational profile associated with CMML cases appears to affect the degree of the bone marrow fibrosis at the time of diagnosis.
Clinicopathologic and molecular genetic comparison of primary uterine serous adenocarcinomas from African American and Caucasian women.
Authors: Aifen Wang, Youguo Chen, Robert W. Holloway, Zhe Pei, Jinsong Yang, Yingyan Zhao
Journal: Journal of Clinical Oncology (2020)

e19092 Background: The study aimed to identify whether there were racial disparities in the clinicopathologic features and genetic mutation characteristics between African American (AA) and Caucasian women with uterine serous carcinoma. Methods: Clinicopathologic features, molecular genetic data of patients with uterine serous carcinoma were obtained from The Cancer Genome Atlas (TCGA), including age of diagnosis, body mass index (BMI), tumor grade, FIGO stage, myometrial invasion, lymph node involvement, overall survival and progression free survival. MLH1, MSH2, MSH6, PMS2, BRCA1, BRCA2, CHEK2, TP53 mutations were involved. A statistical analysis of these parameters was performed for AA and Caucasian women. Results: 44 AA and 97 Caucasian patients with uterine serous carcinoma were analyzed. There were no PMS2 and BRCA2mutations in tumors of African American patients. Compared to Caucasian patients, tumors from AA patients had no statistically significant differences in Lynch syndrome related genes ( MSH2, MSH6, PMS2) (4.5% versus 14.3%, p = 0.149) and HR pathway genes ( BRCA1, BRCA2, CHEK2) (9.1% versus 19.6%, p = 0.09). Tumors from AA patients had no statistically significant differences in alterations of the TP53 gene (79.5% versus 71.3%, p = 0.312). There were no statistically significant differences between the two groups regarding age at diagnosis, BMI, tumor histology, tumor grade, lymph node involvement, myometrial invasion, FIGO stage, overall survival or progression-free survival between the two groups ( p &gt; 0.05). Conclusions: This study identified no statistically significant differences in clinicopathologic features and genetic mutations in AA and Caucasian women with uterine serous carcinomas. Especially, there were no differences in survival identified between two groups. Much larger database may be necessary to be analyzed in future. [Table: see text]
The treatment results in patients with Ewing Sarcoma: The Polish Sarcoma Group Experience.
Authors: Iwona Lugowska, Paulina Jagodzinska-Mucha, Anna Raciborska, Katarzyna Bilska, Hanna Kosela-Paterczyk, Katarzyna Kozak, Anna Dawidowska, Jan Poleszczuk, Piotr Rutkowski
Journal: Journal of Clinical Oncology (2020)

e23503 Background: Ewing Sarcoma is a rare type of aggressive tumor that occurs in bones or in the soft tissue around the bones. The multidisciplinary approach chemotherapy (CHT), radiotherapy (RTH) and surgery (S) is the standard of care. The aim of our study was to analyze prognostic factors and treatment results in patients with Ewing Sarcoma. Methods: 504 patient with Ewing sarcoma treated between 1998 and 2019, F:M 1:1.34, with metastases at presentation was 195 patients (39%), axial localization was in 277 patients (55%). All patient were treated with multimodal treatment based on chemotherapy, radiotherapy and surgery. Kaplan-Meier estimator, log rank test and multivariate Cox model were used for statistical analysis. Results: Five year overall survival (5y-OS) was 54% (CI:49-60%), prognostic factors were: gender (5y-OS for females and males equal to 63% and 48%, respectively), age (5y-OS stratified patients between &lt; 10y; 10-15y; 15-25 and 25+ was 65%, 70%, 41% and 55%;p &lt; 0.001), metastases (5y-OS in group with M1 was 31% and in M0 - 70%; p &lt; 0.001), type of local treatment (5y-OS in group CHT/S/RTH was 61%, CHT/S 59%, only RTH 50% and palliative treatment without local treatment equals 12%; p &lt; 0.001). Multivariate Cox analysis revealed death hazard dependence on gender (male vs. female; HR = 1.80; p &lt; 0.01), metastatic status (M1 vs. M0; HR = 2.91; p &lt; 0.001), bone/bone marrow involvement (present vs. absent; HR = 2.10; p &lt; 0.01) and chemotherapy regime (other vs. VIDE/VAI; HR = 0.69; p = 0.049). Conclusions: The treatment results in Ewing sarcoma are significantly better in children than in adults, which can be related to the more intensive chemotherapy regiments applied. The treatment should be provided in referral centers and based on up-to-dated guideline.
直立倾斜试验与儿童不明原因晕厥
Authors: 隋凤轩, 黄晓萍, 管英伟, 张瑞云, 于金凤
Journal: BMJ (2005)

晕厥是一种常见的临床症状,部分晕厥患者经过详细的心血管和神经系统检查结果均正常,被列为不明原因晕厥,约占所有晕厥患儿的80%[1].自1986年直立倾斜试验(head-up tilt test, HUT)被报告用于不明原因晕厥的诊断以来,经过多年的研究,目前这一检查已被国内外公认为诊断和鉴别诊断不明原因晕厥的有效检查方法,HUT阳性亦为公认的诊断不明原因晕厥的主要指标之一[1] 。
Pastoral care of cancer patients: Defining utilization of services at a comprehensive cancer center.
Authors: Elizabeth Palmer, Anghela Paredes, Madison Hyer, Timothy M. Pawlik
Journal: Journal of Clinical Oncology (2020)

e24171 Background: Addressing the religious/spiritual needs of patients is an important component of comprehensive cancer care. Patients often report that providers infrequently engage them about their needs during treatment. In addition, providers cite inadequate training as a significant barrier to providing spiritual care. While patients may benefit from the presence of a spiritual care specialist during cancer treatment, the utilization and content of these services are not well defined. We sought to characterize utilization of pastoral care (PC) services, as well as delineate differences in PC utilization among patients with cancer. Methods: Data on patients being treated for cancer at a Comprehensive Cancer Center between 2015-2018 were obtained from the electronic medical record. Overall utilization, type of PC services utilized, as well as factors associated with use of PC were assessed. Analyses included descriptive statistics and logistic regression. Results: Among 14,322 cancer patients, roughly one-third (n = 5166, 36.1%) had at least one PC encounter during their cancer treatment. Interventions most frequently provided by PC included supportive presence (93.5%) and active listening (86.6%), while the most frequently explored topics were treatment expectations (59.8%), issues with faith/beliefs (42.9%), and available coping mechanisms (35.4%). Patients diagnosed with colorectal (OR:1.42, 95%CI:1.07-1.89), liver (OR:2.41, 95%CI:1.80-3.24), or pancreatic cancer (OR:1.43, 95%CI:1.02-2.00) were more likely to utilize PC services compared with other cancers. Patients that identified as Catholic (OR:1.47, 95%CI:1.17-1.84) or Christian (OR:1.73, 95%CI:1.39-2.15) were more likely to request PC services (both p &lt; 0.001) than individuals who had no religious preference/affiliation. Among surgical patients (n = 1,174), the majority of encounters with PC services were in the postoperative setting (n = 801, 70.6%). Patients most often reported that PC helped with verbalization of their feelings (93.6%) and helped reduce stress (76.9%). Conclusions: Over one-third of patients with cancer interacted with PC and received services that often addressed both psychosocial and spiritual concerns. Overall PC utilization and types of PC services rendered varied relative to demographic and religious factors. Providers should be aware of varying patient religious/spiritual needs so as to optimize the entire cancer care experience for patients.